Genonto - A Gamechanger in the Fight Against the Opioid Epidemic
Genonto's Process involves genetic predisposition testing and solutions for dependencies and substance use disorders. Better personal information allows for better lifestyle and wellness choices.
By: In Focus Brands
In many cases, for patients who present with acute or chronic pain, it is often standard practice to prescribe narcotic pain relief medication.
This can be a deadly formula for those patients who are genetically predisposed to addiction. But how to determine if this predisposition exists?
There currently exists genetic testing that examines part of the genome to detect the likelihood that a person will develop various treatable diseases such as breast cancer, but this testing is inadequate for revealing the genes linked to addiction disease.
Genonto is the leader in using genetic sequencing to detect genes linked to opioid and other addiction diseases. Their mobile platform uses a proprietary methology to examine the whole exome (WES) for detecting the presence of those genes which indicate a person is at risk for developing addiction.
Genonto's CEO, Phillip Clifford notes, "What we are doing here at Genonto is identifying the genes that are linked to addictive diseases, that indicate a person's likelihood to become addicted. This vital information can inform prescribers when opioids are contraindicated, so that a non-narcotic pain reliever or alternative therapy options can be explored and/or can be prescribed instead."
Clifford continues, "This can help prevent prescribing medications that may put susceptible patients on the slippery slope to addiction, or worse. This is preventive medicine in its highest form."
For those already suffering from the malabsorption and gut disorders common to those with addiction to substances including alcohol, opioids, and illegal drugs, Genonto has another solution.
Genonto creates and engineers patient specfic, genetically-
For more information, please contact: BobM@genonto.com.
Genonto is the leader in genetic sequencing to detect genes linked to opioid dependency and other dependence diseases. The mobile platform uses a proprietary methodology to examine the whole exome (WES) for detecting the presence of those genes which indicate a person is at risk for developing addictions and dependencies with the goal of preventative strategies.